J.ophthalmol.(Ukraine).2015;6:64-67.

https://doi.org/10.31288/oftalmolzh201566467

Changes in the basis of vitreous body in case of uveitis treated by adalimumab

N.V. Panchenko, Doctor of Medical Sciences, prof., T.A. Khramova, PhD in Medical Sciences, A.I. Litvishchenko, MD, G.S. Sarkisian, MD, M.N. Samofalova, MD, E.N. Gonchar, PhD student, M.V. Friantseva

Kharkov National Medical University 

Kharkov(Ukraine)

Keywords: uveitis, Adalimumab, changes in the basis of vitreous body

Objective of the research is to study the dynamics of changes in the basis of vitreous body in case of uveitis treated by Adalimumab.

Material and methods. 5 year old patient S. with recurrent anterior uveitis on the background of juvenile arthritis was observed.

Results. After 4 months of treatment by Adalimumab (20 mg 1 time every 2 weeks combined with methotrexate 10 mg 1 time a week) an exudate has reabsorbed in the prebasal sections of the vitreous body, and after seven months - in the basal ones. During the year no uveitis exacerbations were checked.

Conclusions. When uveitis is treated by Adalimumab the exudate is reabsorbed more slowly in basal sections of the vitreous body. Usage of Adalimumab in the treatment of uveitis is effective and in combination with methotrexate helps to prevent relapses. 

 

References

  1. Panchenko NV, Samofalova MN, Borisova LI. [Proinflammatory cytokines in patients with uveitis complicated by optic neuritis]. Tavricheskii medico-biol. Vestnik. Proceedings of scientific and practical conference with international participants “Azarovskii reading. Neuroophtalmology, pathology of the retina”. Sudak, 2011. Tavricheskii medico-biol. vestnik. 2011; 14(4:2):398-399. Russian.
  2. Aikawa NE. De Carvalho JF, Silva CA et al. Immunogenicity of anti-TNF a agents in autoimmune diseases. Clinic. Rev. Allerg. Immunol. 2010;38:2-3:82-89. 
  3. Beister S, Deuter C, Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007;91:319-324.
  4. Bou R, Iglesias E, Ant?n J. Treatment of uveitis associated with juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 2014;16(8):437.
  5. Chylack LT. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2):217-223.
  6. Foster CS, Tufail F, Waheed NK et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 2003;121(4):437-440. 
  7. Gallagher M, Quinones K, Cervantes-Casta?eda RA et al. Biological response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 2007;91(10):1341-1344.
  8. Guignard S, Gossec L, Salliot C et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in spondylarthropathy patients: a retrospective study. Ann. Rheum. Dis. 2006;65(12):1631-1634.
  9. Guijo PV, Lacomba SM, Hernandez SM et al. Tumor necrosis factor alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27. Curr. Med. Res. Opin. 2004;20:155–157.
  10. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur. J. Ophthalmol. 2007;17(5):743-748.
  11. Heinz C, Mingels A, Goebel C, Fuchsluger T, Heiligenhaus A. Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical course. J. Rheumatol. 2008;35:1403-1407.
  12. Kanski JJ. Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye (Lond). 1988;2:641–645.
  13. Kotaniemi K, S?il? H,  Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin. Ophthalmol. 2011;5:1425–1429.
  14. Lacomba SM, Mart?n MC, Galera GJM et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251-255.
  15. La Torre F, Cattalini M, Teruzzi B et al. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res. Notes. 2014;7:316.
  16. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. In: Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. N. Engl. J. Med. 2008;359:810-820.
  17. Ramanan AV, Dick AD, Benton D et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis. SYCAMORE Trial. 2014;15:14.
  18. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study. Arthritis Rheum. 2007;56:647-657.
  19. Semeraro F, Arcidiacono B, Nascimbeni G et al. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug. Des. Devel. Ther. 2014;24(8):341-348.
  20. Simonini G, Taddio A, Cattalini M. et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. Hoboken. 2011;63(4):612-618.
  21. Tynj?l? P, Kotaniemi K, Lindahl P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. Oxford. 2008;47(3):339-344. 
  22. Vasquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006;149(4):572-575.
  23. Zulian F, Birolo C, Zannin ME. Treatment approach for juvenile idiopathic arthritis-related uveitis. In: Department of Pediatrics, University of Padova, Italy. Current Pediatrics. 2012;11(5):36-44.